Should we advise patients to treat migraine attacks early: methodologic issues

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Triptan trials traditionally mandate treatment for moderate to severe migraine pain.
• This approach ensures migraine-specific treatment, minimizes placebo effects, and standardizes baseline pain levels.
• Clinical practice differs, with theoretical benefits suggested for early migraine treatment.

Purpose of the Study:

• To evaluate the methodological issues and scientific support for early migraine treatment with triptans.
• To differentiate between slowly and rapidly progressing migraine attacks regarding early treatment efficacy.
• To establish optimal trial designs for assessing early migraine treatment.

Main Methods:

• Critically analyze existing studies on early versus late migraine treatment.
• Highlight the need for placebo-controlled, blinded trials assessing therapeutic gain.
• Emphasize the importance of the sustained pain-free endpoint and distinguishing attack progression rates.

Main Results:

• Current evidence lacks scientific support for advising early migraine treatment.
• Early treatment may be conflated with treating mild pain in specific attack types.
• Early treatment might increase the risk of medication overuse headaches.

Conclusions:

• No scientific basis currently exists to recommend early migraine treatment.
• Further research is needed to distinguish migraine attack types and their treatment timing.
• Patients should take triptans upon recognizing migraine onset, excluding the aura phase.